Insight

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah and Vania Hungria

Oct 26, 2024, 12:33

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, shared an article by Vania Hungria, Department of hematology at Santa Casa de São Paulo, on X:

” Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?”

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Authors: Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, D.Phil and Ana Carolina Ribas de Almeida

Al-Ola A Abdallah

Al-Ola A Abdallah Ana Carolina Ribas de Almeida cancer Christopher Ward combination therapy D.Phil Marek Hus Myeloma OncoDaily Oncology P. Joy Ho Pawel Robak Santa Casa de São Paulo University of Kansas Medical Center Vania Hungria Vera Zherebtsova

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage